Cargando…

S241: ITACONATE INHIBITS TH1 DIFFERENTIATION AND ACUTE GRAFT-VERSUS-HOST DISEASE VIA NRF2

Detalles Bibliográficos
Autores principales:	Gong, Huanle, Shen, Yaoyao, Xu, Yang, Wu, Depei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428343/ http://dx.doi.org/10.1097/01.HS9.0000967876.90124.1f

Ejemplares similares

S240: TARGETING PRMT1 ALLEVIATES CHRONIC GRAFT-VERSUS-HOST DISEASE BY REDUCING T AND B PATHOGENICITY
por: Zhao, Xiaoyan, et al.
Publicado: (2023)

Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate
por: Han, Jingjing, et al.
Publicado: (2017)

S242: MAST CELLS ARE MEDIATORS OF INFLAMMATORY EFFECTOR CELL RECRUITMENT AND FIBROSIS IN DERMAL CHRONIC GRAFT-VERSUS-HOST DISEASE
por: Palaniyandi, Senthilnathan, et al.
Publicado: (2023)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
por: Locatelli, Franco, et al.
Publicado: (2023)

S246: JAK/ROCK INHIBITOR TQ05105 FOR GLUCOCORTICOID-REFRACTORY OR -DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE: UPDATED RESULTS OF A PHASE 1B/2 STUDY
por: Zhao, Yanmin, et al.
Publicado: (2023)

High stearic acid diet modulates gut microbiota and aggravates acute graft-versus-host disease
por: Yang, Bingyu, et al.
Publicado: (2021)

Oral Chronic Graft-Versus-Host Disease
por: Dean, David, et al.
Publicado: (2022)

AAPM task group 241 – MR-guided focused ultrasound
por: Farahani, Keyvan, et al.
Publicado: (2015)

S122: MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.
por: Hakobyan, Mariam, et al.
Publicado: (2023)

Graft versus host disease in humanized mice is differentially controlled by CD28 and CD80/86 antagonists
por: Poirier, Nicolas, et al.
Publicado: (2012)

IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity
por: Lv, Kangkang, et al.
Publicado: (2022)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

S105: CLONAL DIFFERENTIATION TRAJECTORIES OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AT SINGLE CELL LEVEL
por: Geßner, Alec, et al.
Publicado: (2023)

S177: JAK INHIBITION AND COMBINATION THERAPY IN THE TREATMENT OF MURINE BONE MARROW FAILURE
por: Feng, Xingmin, et al.
Publicado: (2023)

S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
por: Zhang, Yi, et al.
Publicado: (2023)

IL-Y Aggravates Murine Chronic Graft-Versus-Host Disease by Enhancing T and B Cell Responses
por: Wan, Li, et al.
Publicado: (2020)

S309: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585
por: Lambert, Sylviane, et al.
Publicado: (2023)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S288: DIFFERENTIAL RECOVERY OF MACROPHAGE IRON DEFICIENCY BY ORAL IRON FORMULATIONS DETERMINES CELL INFLAMMATORY ACTIVATION IN ANEMIC CONDITIONS
por: Antypiuk, Ada, et al.
Publicado: (2023)

S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY
por: Berning, Philipp, et al.
Publicado: (2023)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

S205: INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS
por: Gleitz, Hélène, et al.
Publicado: (2023)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

S229: PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA: A PHASE III RANDOMIZED, CONTROLLED STUDY
por: Yahng, Seung-Ah, et al.
Publicado: (2023)

The role of itaconate in host defense and inflammation
por: Peace, Christian G., et al.
Publicado: (2022)

Metabolite itaconate in host immunoregulation and defense
por: Yang, Wenchang, et al.
Publicado: (2023)

S209: TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS
por: Jungius, Sarah, et al.
Publicado: (2023)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
por: Kok, Chung, et al.
Publicado: (2023)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

S141: INHIBITION OF MYC TRANSLATION THROUGH TARGETING OF THE NEWLY IDENTIFIED PHB-EIF4F COMPLEX AS THERAPEUTIC STRATEGY INCHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Largeot, Anne, et al.
Publicado: (2023)

S281: TMPRSS6 INHIBITION WITH A MONOCLONAL ANTIBODY IMPROVES RED BLOOD CELL HEALTH AND IRON OVERLOAD IN A MOUSE MODEL OF BETA-THALASSEMIA
por: Lob, Heinrich, et al.
Publicado: (2023)

S241. FACTORS ASSOCIATED WITH EARLY RISK OF DISENGAGEMENT FROM EARLY PSYCHOSIS INTERVENTION SERVICES
por: Kozloff, Nicole, et al.
Publicado: (2020)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
por: Liu, Shuangzhu, et al.
Publicado: (2018)

Sinunasal ultrastructure of the transplant hematopoietic stem cell and chronic graft-versus-host disease with rhinosinusitis
por: Ortiz, Erica, et al.
Publicado: (2013)

Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft‐versus‐host disease prophylaxis
por: Garming Legert, Karin, et al.
Publicado: (2020)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9q7bcq3ek4mn2oltpr14dg8a0b